{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T12:17:17Z","timestamp":1777033037002,"version":"3.51.4"},"reference-count":27,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Immunological Medicine"],"published-print":{"date-parts":[[2025,1,2]]},"DOI":"10.1080\/25785826.2024.2418164","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T12:18:18Z","timestamp":1729685898000},"page":"70-77","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["Investigating the impact of tocilizumab on serum cytokines concentrations in Japanese FMF patients: a sub-analysis of the NUH01FMF study"],"prefix":"10.1080","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2077-4428","authenticated-orcid":false,"given":"Tomohiro","family":"Koga","sequence":"first","affiliation":[{"name":"Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences","place":["Nagasaki, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuntaro","family":"Sato","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital","place":["Nagasaki, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaori","family":"Furukawa","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences","place":["Nagasaki, Japan"]},{"name":"National Research Center for the Control and Prevention of Infectious Diseases, Nagasaki University","place":["Nagasaki, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital","place":["Nagasaki, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Kawakami","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences","place":["Nagasaki, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2024,10,23]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ejhg.5200658"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng0997-25"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/13497413.2018.1481579"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(67)90167-2"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.2147\/BTT.S102954"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2020.1800558"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0049-0172(98)80028-0"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2017.03.006"},{"issue":"4","key":"e_1_3_4_10_1","first-page":"S34","article-title":"Levels of interleukin-6 (IL-6) and its soluble receptor (sIL-6R) in familial Mediterranean fever (FMF) patients and their first degree relatives","volume":"22","author":"Oktem S","year":"2004","unstructured":"Oktem S, Yavuzsen TU, Seng\u00fcl B, et\u00a0al. Levels of interleukin-6 (IL-6) and its soluble receptor (sIL-6R) in familial Mediterranean fever (FMF) patients and their first degree relatives. Clin Exp Rheumatol. 2004;22(4 Suppl 34):S34\u2013S6.","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2008.03.017"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2010.181"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/03009742.2017.1363281"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003449"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.021908.132612"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.956795"},{"key":"e_1_3_4_17_1","first-page":"1535","article-title":"A randomised, double-blind, placebo-controlled phase III trial on the efficacy and safety of tocilizumab in patients with \u00adfamilial Mediterranean fever","volume":"40","author":"Koga T","year":"2022","unstructured":"Koga T, Sato S, Hagimori N, et\u00a0al. A randomised, double-blind, placebo-controlled phase III trial on the efficacy and safety of tocilizumab in patients with \u00adfamilial Mediterranean fever. Clin Exp Rheumatol. 2022;40:1535\u20131542.","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-018-3105-6"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep33123"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/JLB.3A0820-207R"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar1969"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-9-18"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-008-0125-1"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/15257770.2022.2127766"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxaa078"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/03009742.2022.2028382"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.121389"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22765"}],"container-title":["Immunological Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/25785826.2024.2418164","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T13:01:10Z","timestamp":1740402070000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/25785826.2024.2418164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,23]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,2]]}},"alternative-id":["10.1080\/25785826.2024.2418164"],"URL":"https:\/\/doi.org\/10.1080\/25785826.2024.2418164","relation":{},"ISSN":["2578-5826"],"issn-type":[{"value":"2578-5826","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,23]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=timm20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=timm20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-08-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}